Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:1435:57-84.
doi: 10.1007/978-3-031-42108-2_4.

European Practice for CDI Treatment

Fidelma Fitzpatrick  1   2 , Robert Brennan  3 , Joffrey van Prehn  4 , Mairead Skally  3   5 , Melissa Brady  6 , Karen Burns  5 , Christopher Rooney  7   8 , Mark H Wilcox  9   10
Affiliations

European Practice for CDI Treatment

Fidelma Fitzpatrick et al. Adv Exp Med Biol. 2024.

Abstract

Clostridioides difficile infection (CDI) remains a significant cause of morbidity and mortality worldwide. Historically, two antibiotics (metronidazole and vancomycin) and a recent third (fidaxomicin) have been used for CDI treatment; convincing data are now available showing that metronidazole is the least efficacious agent. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) management guidance for CDI were updated in 2021. This guidance document outlines the treatment options for a variety of CDI clinical scenarios and for non-antimicrobial management (e.g., faecal microbiota transplantation, FMT). One of the main changes is that metronidazole is no longer recommended as first-line CDI treatment. Rather, fidaxomicin is preferred on the basis of reduced recurrence rates with vancomycin as an acceptable alternative. Recommended options for recurrent CDI now include bezlotoxumab as well as FMT.A 2017 survey of 20 European countries highlighted variation internationally in CDI management strategies. A variety of restrictions were in place in 65% countries prior to use of new anti-CDI treatments, including committee/infection specialist approval or economic review/restrictions. This survey was repeated in November 2022 to assess the current landscape of CDI management practices in Europe. Of 64 respondents from 17 countries, national CDI guidelines existed in 14 countries, and 11 have already/plan to incorporate the ESCMID 2021 CDI guidance, though implementation has not been surveyed in 6. Vancomycin is the most commonly used first-line agent for the treatment of CDI (n = 42, 66%), followed by fidaxomicin (n = 30, 47%). Six (9%) respondents use metronidazole as first-line agent for CDI treatment, whereas 22 (34%) only in selected low-risk patient groups. Fidaxomicin is more likely to be used in high-risk patient groups. Availability of anti-CDI therapy influenced prescribing in six respondents (9%). Approval pre-prescription was required before vancomycin (n = 3, 5%), fidaxomicin (n = 10, 6%), bezlotoxumab (n = 11, 17%) and FMT (n = 10, 6%). Implementation of CDI guidelines is rarely audited.Novel anti-CDI agents are being evaluated; it is not yet clear what will be the roles of these agents. The treatment of recurrent CDI is particularly troublesome, and several different live biotherapeutics are being developed, in addition to FMT.

Keywords: Anti-CDI agents; C. difficile prophylaxis; C. difficile treatment; CDI guidelines; Novel C. difficile agents.

PubMed Disclaimer

References

    1. A randomized, double-blind, active controlled study to evaluate the safety and tolerability of ridinilazole compared with vancomycin and to assess the pharmacokinetics of ridinilazole in adolescent subjects (aged 12 to <18 years) with Clostridioides ClinicalTrials.gov identifier: NCT04802837. Updated October 13, 2022. https://ClinicalTrials.gov/show/NCT04802837 . Accessed 22 Mar 2023
    1. A phase 3, placebo-controlled, randomized, observer-blinded study to evaluate the efficacy, safety, and tolerability of a Clostridium difficile vaccine in adults 50 years of age and older. ClinicalTrials.gov identifier: NCT03090191. Updated February 13, 2023. https://ClinicalTrials.gov/show/NCT03090191 . Accessed 16 Mar 2023
    1. ActelionLtd (2017) Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
    1. Alang N, Kelly CR (2015) Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2(1):ofv004. https://doi.org/10.1093/ofid/ofv004 - DOI - PubMed - PMC
    1. Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH (2015) SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 70(1):182–189. https://doi.org/10.1093/jac/dku324 - DOI - PubMed

LinkOut - more resources